Evidence map›Paper›PMID 17513580›Full record

ArticleApplied and environmental microbiology2007

Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac disease.

Carlo G Rizzello, Maria De Angelis, Raffaella Di Cagno, Alessandra Camarca, Marco Silano, Ilario Losito, Massimo De Vincenzi, Maria D De Bari, Francesco Palmisano, Francesco Maurano and 2 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Applied and environmental microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01257620 (Exploratory, Randomized, Double-blind, Placebo-Controlled Study on the Effects of Bifidobacterium Infantis in Active Celiac Disease), which is not on this map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01257620 nacompletednot on this mapstarted 2010, after this paper: background citation

Exploratory, Randomized, Double-blind, Placebo-Controlled Study on the Effects of Bifidobacterium Infantis in Active Celiac Disease

TypeinterventionalSponsorBai, Julio M.D.Ran2010 to 2011Enrolled22ConditionsCeliac DiseaseArmsProbiotic
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 272 citations in OpenAlex.

  1. Pooled it
  2. Novel probiotic preparation withMicrobiology spectrum · 2024
    Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Probiotics: a supplement to the gluten-free diet in celiac disease.Gastroenterology and hepatology from bed to bench · 2025
    Review
  8. Article
  9. Review
  10. Probiotics to Prevent Celiac Disease and Inflammatory Bowel Diseases.Advances in experimental medicine and biology · 2024
    Review
  11. Review
  12. Review
  13. The Ability of the YeastFoods (Basel, Switzerland) · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Characterization ofFoods (Basel, Switzerland) · 2021
    Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Carlo G RizzelloDepartment of Plant Protection and Applied Microbiology, University of Bari, Bari, Italy.
Maria De Angelis
Raffaella Di Cagno
Alessandra Camarca
Marco Silano
Ilario Losito
Massimo De Vincenzi
Maria D De Bari
Francesco Palmisano
Francesco Maurano
Carmen Gianfrani
Marco Gobbetti
University of Bari Aldo Moro · ITInstitute of Food Science · ITIstituto Superiore di Sanità · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Presently, the only effective treatment for celiac disease is a life-long gluten-free diet. In this work, we used a new mixture of selected sourdough lactobacilli and fungal proteases to eliminate the toxicity of wheat flour during long-time fermentation. Immunological (R5 antibody-based sandwich and competitive enzyme-linked immunosorbent assay [ELISA] and R5 antibody-based Western blot), two-dimensional electrophoresis, and mass spectrometry (matrix-assisted laser desorption ionization-time of flight, strong-cation-exchange-liquid chromatography/capillary liquid chromatography-electrospray ionization-quadrupole-time of flight [SCX-LC/CapLC-ESI-Q-TOF], and high-pressure liquid chromatography-electrospray ionization-ion trap mass spectrometry) analyses were used to determine the gluten concentration. Assays based on the proliferation of peripheral blood mononuclear cells (PBMCs) and gamma interferon production by PBMCs and intestinal T-cell lines (iTCLs) from 12 celiac disease patients were used to determine the protein toxicity of the pepsin-trypsin digests from fermented wheat dough (sourdough). As determined by R5-based sandwich and competitive ELISAs, the residual concentration of gluten in sourdough was 12 ppm. Albumins, globulins, and gliadins were completely hydrolyzed, while ca. 20% of glutenins persisted. Low-molecular-weight epitopes were not detectable by SCX-LC/CapLC-ESI-Q-TOF mass spectrometry and R5-based Western blot analyses. The kinetics of the hydrolysis of the 33-mer by lactobacilli were highly efficient. All proteins extracted from sourdough activated PBMCs and induced gamma interferon production at levels comparable to the negative control. None of the iTCLs demonstrated immunoreactivity towards pepsin-trypsin digests. Bread making was standardized to show the suitability of the detoxified wheat flour. Food processing by selected sourdough lactobacilli and fungal proteases may be considered an efficient approach to eliminate gluten toxicity.

Indexed as

Blotting, WesternBreadCeliac DiseaseCells, CulturedElectrophoresis, Gel, Two-DimensionalEnzyme-Linked Immunosorbent AssayFermentationFungiGlutensHumansInterferon-gammaIntestinesLactobacillusLeukocytes, MononuclearPeptide HydrolasesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationGlutensInterferon-gammaPeptide Hydrolases

Identifiers

PMID17513580
PMCPMC1932817
OpenAlexW2137094219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.